March 28 | 2019
2cureX receives Notice of Allowance from the United States Patent Office
Read more
March 28 | 2019
2cureX erhåller Notice of Allowance från det amerikanska patentverket
Read more
March 14 | 2019
Notice of extraordinary general meeting in 2cureX AB (publ)
Read more
March 12 | 2019
2cureX utvidgar verksamheten till förebyggande cancermedicin
Read more
March 12 | 2019
2cureX expands its activities to preventive cancer medicine
Read more
March 1 | 2019
2cureX offentliggör bokslutskommuniké för räkenskapsåret 2018
Read more
March 1 | 2019
2cureX publishes year-end report for the fiscal year 2018
Read more
February 20 | 2019
Correction – Lack of reference to MAR – 2cureX meddelar positiva resultat från pågående klinisk studie med kraftigt förbehandlade kolorektalcancerpatienter
Read more
February 20 | 2019
Correction – Lack of reference to MAR – 2cureX reports positive results from an ongoing clinical trial in heavily pre-treated colorectal cancer patients
Read more
December 10 | 2018
2cureX is accelerating the launch of IndiTreat®
Read more
December 10 | 2018
2cureX accelererar lanseringen av IndiTreat®
Read more
November 16 | 2018
Vejle universitetssjukhus och 2cureX har erhållit godkännande att inleda en klinisk studie i bukspottkörtelcancer
Read more
November 16 | 2018
The University Hospital, Vejle Hospital and 2cureX have received approval to start a clinical trial in pancreatic cancer
Read more
October 9 | 2018
2cureX announces CE-IVD marking of its IndiTreat test
Read more
October 9 | 2018
2cureX meddelar godkänd CE-IVD-märkning av sitt IndiTreat-test
Read more
August 22 | 2018
2cureX stärker sin patentportfölj med nytt godkänt europeiskt patent
Read more
August 22 | 2018
2cureX strengthen its patent portfolio with the granting of a new European patent
Read more
June 21 | 2018
2cureX presents positive clinical data from its IndiTreat® CRC trial at ESMO in Barcelona
Read more